Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001104659-25-039436·AbbVie Biotechnology Ltd
Schedule 13G ownership disclosure
CARISMA THERAPEUTICS INC
Common Stock, $0.001 par value · CUSIP: 14216R101
Event date: 2025-03-31
- Filing-level shares
- 1,855,871.00
- Percent of class
- 4.4%
- AbbVie Biotechnology Ltd.
Shares: 1,855,871.00 · Class: 4.4%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-039436
- Form type
- SCHEDULE 13G/A
- Filer
- AbbVie Biotechnology Ltd
- CIK
- CIK 2014668
- Filed
- Apr 25, 2025
- Reporting period
- Mar 31, 2025
- Description
- Schedule 13G beneficial ownership